Cargando…

Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals

INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xue‐Ning, Kuo, Kevin, Yang, Yu‐Xiang, Li, Hong‐Qi, Chen, Shi‐Dong, Cui, Mei, Tan, Lan, Dong, Qiang, Yu, Jin‐Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158163/
https://www.ncbi.nlm.nih.gov/pubmed/34095433
http://dx.doi.org/10.1002/dad2.12198
_version_ 1783699826817368064
author Shen, Xue‐Ning
Kuo, Kevin
Yang, Yu‐Xiang
Li, Hong‐Qi
Chen, Shi‐Dong
Cui, Mei
Tan, Lan
Dong, Qiang
Yu, Jin‐Tai
author_facet Shen, Xue‐Ning
Kuo, Kevin
Yang, Yu‐Xiang
Li, Hong‐Qi
Chen, Shi‐Dong
Cui, Mei
Tan, Lan
Dong, Qiang
Yu, Jin‐Tai
author_sort Shen, Xue‐Ning
collection PubMed
description INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess the longitudinal neuropathological and clinical correlates of baseline SCI, via linear mixed‐effects and Cox proportional‐hazard models. Cross‐lagged panel models were used in specific time waves. RESULTS: SCI individuals had a faster increase in brain amyloid burden and a higher risk of conversion. They also showed greater rates of cerebrospinal fluid (CSF) phosphorylated tau (p‐tau)(181) increase and glucose metabolism decrease. In addition, baseline SCI predicted worse clinical progression, whereas multi‐domain SCI advanced faster compared to the single domain group. DISCUSSION: Baseline SCI could be an imperative prediction indicator of clinical and pathological progression. It enables cognitive measures to be informative at a very early stage and provided objective criteria for high‐risk population screening.
format Online
Article
Text
id pubmed-8158163
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81581632021-06-03 Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals Shen, Xue‐Ning Kuo, Kevin Yang, Yu‐Xiang Li, Hong‐Qi Chen, Shi‐Dong Cui, Mei Tan, Lan Dong, Qiang Yu, Jin‐Tai Alzheimers Dement (Amst) Cognitive & Behavioral Assessment INTRODUCTION: Subtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement. METHODS: A total of 816 cognitively normal individuals were enrolled to assess the longitudinal neuropathological and clinical correlates of baseline SCI, via linear mixed‐effects and Cox proportional‐hazard models. Cross‐lagged panel models were used in specific time waves. RESULTS: SCI individuals had a faster increase in brain amyloid burden and a higher risk of conversion. They also showed greater rates of cerebrospinal fluid (CSF) phosphorylated tau (p‐tau)(181) increase and glucose metabolism decrease. In addition, baseline SCI predicted worse clinical progression, whereas multi‐domain SCI advanced faster compared to the single domain group. DISCUSSION: Baseline SCI could be an imperative prediction indicator of clinical and pathological progression. It enables cognitive measures to be informative at a very early stage and provided objective criteria for high‐risk population screening. John Wiley and Sons Inc. 2021-05-27 /pmc/articles/PMC8158163/ /pubmed/34095433 http://dx.doi.org/10.1002/dad2.12198 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Cognitive & Behavioral Assessment
Shen, Xue‐Ning
Kuo, Kevin
Yang, Yu‐Xiang
Li, Hong‐Qi
Chen, Shi‐Dong
Cui, Mei
Tan, Lan
Dong, Qiang
Yu, Jin‐Tai
Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title_full Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title_fullStr Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title_full_unstemmed Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title_short Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals
title_sort subtle cognitive impairment as a marker of alzheimer's pathologies and clinical progression in cognitively normal individuals
topic Cognitive & Behavioral Assessment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158163/
https://www.ncbi.nlm.nih.gov/pubmed/34095433
http://dx.doi.org/10.1002/dad2.12198
work_keys_str_mv AT shenxuening subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT kuokevin subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT yangyuxiang subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT lihongqi subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT chenshidong subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT cuimei subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT tanlan subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT dongqiang subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT yujintai subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals
AT subtlecognitiveimpairmentasamarkerofalzheimerspathologiesandclinicalprogressionincognitivelynormalindividuals